LexcorpThe expenses last 2 quarters were for ATL1103 Phase I...

Lexcorp

The expenses last 2 quarters were for ATL1103 Phase I trial, which was fully funded.
ANP has very low running cost as most researches and trials are on per project basis through contractors and always fully funded at each Phase.

Currently we are waiting for the possible deal with big pharma or confirmation of funding plus initiation of Phase 2 trial. As the Ann is expected within 1-2 weeks based on the time lapse since Phase 1 result, the low vol just indicates the holding pattern.

Similarly, no chart indicator was preparing you for the rise from 0.6 to
2.4 in 4 months unless you know what is going on at ANP.

I can safely say that no chart will prepare you for the next leg up once ATL1103 Phase 2 human trial is in motion. And no chart will prepare you when ATL 1101 for prostate cancer is into Phase 1/2 clinical trial within the next 3 months. Of course a wild card reactivation of ATL1102 for MS with Teva will see ANP back to above 10c

Downramp at your own peril

As always, DYOR Before posting to avoid embarassing yourself.